Physician profile
Peter J Bruno
NPI 1912952185
$7,000.60
in general payments reported to CMS, 2019-2025
35 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,322 · 2020: $419 · 2021: $1,303 · 2022: $1,485 · 2023: $1,199 · 2024: $923 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,456 · Education: $16.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,455.54 |
| Education | $16.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,377.06 | 2019-2025 | Synthroid |
| Glaxosmithkline, LLC. | $1,168.49 | 2020-2025 | Trelegy Ellipta, Nucala |
| Amgen INC. | $785.56 | 2019-2024 | Repatha, Otezla |
| Bausch Health US, LLC | $529.99 | 2022-2024 | Wellbutrin, Aplenzin |
| Pfizer INC. | $430.80 | 2019-2025 | |
| Axsome Therapeutics, INC. | $225.31 | 2022-2023 | Sunosi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $219.97 | 2019-2021 | |
| Antares Pharma, INC. | $193.93 | 2019-2023 | Xyosted, Nocdurna, Tlando |
| Amarin Pharma, INC. | $189.66 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $164.60 | 2019-2024 | Trintellix |
| Allergan, INC. | $159.44 | 2019-2020 | |
| Almatica Pharma LLC | $142.19 | 2023-2025 | Loreev Xr, Gralise, Sertraline Hcl |
| E.R. Squibb & Sons, L.L.C. | $141.07 | 2019-2023 | Eliquis |
| Astrazeneca Pharmaceuticals LP | $126.26 | 2019-2023 | |
| Esperion Therapeutics, INC. | $108.79 | 2020-2022 |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Bruno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.